Genmab AS

Genmab AS AAQS

The The AAQS of Genmab AS (GMAB) as of Nov 22, 2026 is 6. In the previous year, The AAQS was 6.00 — a change of 0.00% (lower).

AAQS

6

YoY

0.00%

Last updated:

Genmab AS has a current AAQS of 6.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Genmab AS in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Genmab AS AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
6.00 USD
Jan 1, 2019
6.00 USD
Jan 1, 2020
6.00 USD
Jan 1, 2021
6.00 USD
Jan 1, 2022
6.00 USD
Jan 1, 2023
6.00 USD
Jan 1, 2024
6.00 USD
Jan 1, 2025
6.00 USD
The Genmab AS AAQS history
YEARAAQSYoY
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
6—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

The AAQS of Genmab AS is 6 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Genmab AS since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Genmab AS

All Key Metrics — Genmab AS